Stock Market Wire News Logo
Stock Market Wire News Logo
    • Login
    • Sign Up

Ad

Investor Relations

FMI Stock - Foundation Medicine Stock Trading


home / stock / fmi

FMI FMI Quote FMI Short FMI News FMI Articles FMI Message Board

MWN AI Summary *

Foundation Medicine Inc. (NASDAQ: FMI) is a pivotal player in the field of molecular genomics, specializing in advancing precision medicine for cancer treatment. Founded in 2010 and headquartered in Cambridge, Massachusetts, the company is renowned for its robust suite of genomic profiling assays designed to identify the genetic alterations in tumors. This approach aids in determining the most effective therapies for individual patients, enabling personalized treatment plans that align with their unique cancer profiles.

Foundation Medicine's flagship product, FoundationOne, is a comprehensive genomic profiling test that analyzes over 300 genes commonly associated with cancer. This test helps oncologists make informed decisions regarding targeted therapies, eligibility for clinical trials, and prognostics based on the genetic makeup of tumors. The company also offers FoundationOne CDx, a companion diagnostic that gained FDA approval, linking specific therapies to genetic profiles.

In recent years, Foundation Medicine has formed strategic partnerships with various pharmaceutical companies and healthcare organizations, enhancing its capabilities in drug development and enabling better integration of genomic insights into routine cancer care. The collaboration with Roche, which acquired Foundation Medicine in 2018, has significantly expanded its resources and reach in the oncology space.

Financially, FMI has demonstrated resilience, with growth driven by an expanding customer base and increasing adoption of genomic testing in clinical practice. As the healthcare landscape evolves towards more data-driven approaches, Foundation Medicine stands to benefit from the rising demand for precision medicine, particularly as more targeted therapies emerge on the market. With a commitment to innovation in cancer genomics and a strong track record of partnerships, Foundation Medicine Inc. is positioned to be a key resource in transforming cancer care for patients and healthcare providers alike.

MWN AI Analysis *

As of October 2023, Foundation Medicine Inc. (NASDAQ: FMI) remains a key player in the precision medicine sector, primarily focused on genomic profiling to provide insights for cancer treatment. The company's comprehensive genomic profiling (CGP) tests enable oncologists to tailor therapies based on the genetic makeup of individual tumors, positioning FMI as a critical partner in the evolving landscape of personalized healthcare.

The recent trends in the biotech sector, particularly surrounding precision medicine, suggest a robust growth trajectory for Foundation Medicine. Increased emphasis on genetic testing, in light of growing cancer prevalence and advances in targeted therapies, strengthens FMI's market position. Notably, partnerships with pharmaceutical companies have enhanced FMI's visibility and adoption rates of its products, indicating robust revenue streams driven by research collaboration and commercialization of companion diagnostics.

However, potential investors should consider several factors before proceeding. Firstly, the competitive landscape is becoming increasingly crowded as more companies enter the precision medicine space. This heightens the importance of maintaining technological advantage and innovation. Additionally, while FMI benefits from a well-established footprint in the U.S. market, success in global markets remains paramount for sustained growth, especially considering potential regulatory hurdles and regional market saturation.

Financial performance metrics should be closely monitored, especially in terms of revenue growth, gross margins, and R&D expenditure, which are indicative of the company’s future prospects. The earnings reports scheduled for November 2023 will be crucial for understanding FMI's trajectory, especially regarding its capacity to expand its testing offerings and manage costs effectively.

In summary, while Foundation Medicine exhibits strong fundamentals and growth potential in the precision oncology field, investors should maintain a cautious outlook, emphasizing an analysis of upcoming earnings and strategic developments in the competitive landscape. Engaging with FMI's progress could be rewarding, but thorough due diligence is essential.

* MWN AI Summary and Analysis is based on asking OpenAI to summarize and analyze the company and stock symbol.


About | Foundation Medicine Inc. (NASDAQ:FMI)

Foundation Medicine Inc is a molecular diagnostics company that specializes in the evaluation and treatment of cancer. Its products provide genetic information about a patient's cancer that is used by physicians to inform clinical decisions and by biopharmaceutical companies to develop targeted oncology therapies. Foundation Medicine's core molecular information products include FoundationOne, for solid tumors, and FoundationOne Heme, for blood-based cancers and hematologic malignancies. The vast majority of the firm's revenue is generated within the United States.

Quote | Foundation Medicine Inc. (NASDAQ:FMI)

Last:$
Change Percent: 0.00%
Open:$N/A
Close:$137.00
High:$N/A
Low:$N/A
Volume:2,500
Last Trade Date Time:12/31/1969 07:00:00 pm

News | Foundation Medicine Inc. (NASDAQ:FMI)

Message Board Posts | Foundation Medicine Inc. (NASDAQ:FMI)

Subject By Source When
Roche acquires majority stake in FMI @$50/sh PennyStock Alert investorshub 09/16/2019 1:04:06 PM
Congrats to all long!!! Cheetah SPEED investorshub 06/19/2018 1:14:34 PM
$FMI buy 74.90 stocktrademan investorshub 02/19/2018 10:34:46 PM
$FMI PR on FDA/CMS approval of FoundationOne CDx: DewDiligence investorshub 12/01/2017 6:35:27 PM
Looks like serious competition for $FMI: #msg-136227022. DewDiligence investorshub 11/15/2017 7:04:09 PM

MWN AI FAQ **

What are the recent advancements and partnerships that Foundation Medicine Inc. (NASDAQ: FMI) has made in the field of genomic profiling for cancer treatment?

As of October 2023, Foundation Medicine, Inc. has advanced its genomic profiling capabilities through partnerships with leading pharmaceutical companies for precision oncology research and by integrating advanced AI-driven analytics to enhance its genomic assays for cancer treatment.

How does Foundation Medicine Inc. (NASDAQ: FMI) plan to expand its market share amidst increasing competition in the precision medicine sector?

Foundation Medicine Inc. (NASDAQ: FMI) aims to expand its market share by enhancing its genomic profiling technologies, fostering strategic partnerships, and increasing collaboration with healthcare providers to improve patient access to its comprehensive testing solutions in precision medicine.

What financial performance indicators should investors look at for Foundation Medicine Inc. (NASDAQ: FMI) in the upcoming quarterly earnings report?

Investors should focus on revenue growth, gross margins, net income or loss, cash burn rate, operating expenses, and guidance for future performance in the upcoming quarterly earnings report for Foundation Medicine Inc. (NASDAQ: FMI).

How is Foundation Medicine Inc. (NASDAQ: FMI) addressing the regulatory challenges and reimbursement issues associated with its diagnostic products?

Foundation Medicine Inc. (NASDAQ: FMI) is addressing regulatory challenges and reimbursement issues by engaging with regulatory bodies for product approvals, enhancing clinical validation of its diagnostics, and expanding collaborations with payers to secure coverage and reimbursement.

** MWN AI Questions are based on asking OpenAI to ask and answer four questions about the company and stock symbol.

Stock Information

Get FMI Alerts

News, Short Squeeze, Breakout and More Instantly...

Foundation Medicine Inc. Company Name:

FMI Stock Symbol:

NASDAQ Market:

0.00% G/L:

$ Last:

2,500 Volume:

$N/A Open:

$137.00 Close:

Foundation Medicine Inc. Logo

Ad

Investor Relations
RECENT FMI NEWS
  • Research
  • Stock Search
  • News Releases
  • Articles
  • Topics
  • Message Boards
  • Trending Stocks
  • Trending Feed
  • Trending Alerts
  • Watchlist
  • Short Information
  • Stock Wall
  • Link Twitter
  • Sign Up
  • Login
  • Contact

Link your X Account

Link your X Account to Market Wire News

When you linking your X Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your X account.

Be alerted of any news about your stocks and see what other stocks are trending.



Connect with Us

Join our Telegram Alerts Channel

Telegram

Join our Discord

Discord

Get FMI Alerts

Get FMI Alerts

News, Short Squeeze, Breakout and More Instantly...

Sign up or login to continue

Sign up or login to continue.


Forgot password?




Mobile Number Subscribers

Market Wire News provides notifications to customers about updates, service, reminders, or products. Current and new customers of Market Wire News will enter their mobile numbers on a web opt-in form https://marketwirenews.com. Supported Carriers are as follows Alltel, AT&T, Cincinnati Bell, Dobson Cellular Systems, Inter Op, MetroPCS®, Nextel Communications, Sprint PCS, T-Mobile®, U.S. Cellular®, Verizon Wireless, and Virgin Mobile U.S. T-Mobile® is not liable for delayed or undelivered messages. There are no premium charges for joining Market Wire News service. Message and data rates may apply. Subscribers to Market Wire News service may receive up to 500 per month.

How to Opt Out

To opt-out of the Market Wire News program, send or text STOP, END, QUIT, CANCEL or UNSUBSCRIBE to (844) 931-3999. An unsubscribe message will be sent to your number confirming the cancellation, but no more messages will be sent after that one.

Mobile Support

For support or information about a Market Wire News, send or text HELP to (844) 931-3999. Optionally, you may email support@marketwirenews.com.


Disclaimer

This electronic content is for the purposes of solicitation subscriptions for Market Wire News. Market Wire News expects to generate new advertisement revenue resulting from the distribution of this electronic content. The amount of which is unknown at this time. Market Wire News is not a registered investment adviser or broker-dealer. This electronic content does not provide a professional analysis of a any stock financial position. any stock's financial position and all other information regarding the featured Company should be verified directly with any stock. This electronic content is provided as an information service only, and any statements and opinions in this electronic content should not be construed as an offer or solicitation to buy or sell any security. Market Wire News accepts no liability for any loss arising from an investor's reliance on or use of this electronic content. An investment in any company is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. Market Wire News does not own, buy, sell or plans to own, buy, sell, and of any stock's shares. This electronic content contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Please read our full disclaimer for compensation and more detailed information.

Advertise

Brand your company, advertise your products or services with our ad programs.

Advertise

Research

Stock Search

News Releases

Articles

Message Boards

Trending Stocks

Short Information

Stock Wall

Members

Log In

Sign Up

Stay Connected

| X

| Facebook

| BlueSky

| LinkedIn

| Telegram

| Discord


Contact

Privacy

Terms of Service

Disclaimer

© 2025 Market Wire News 1